Identification of small molecule compounds that inhibit the HIF-1 signaling pathway by Xia, Menghang et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
Molecular Cancer
Open Access Research
Identification of small molecule compounds that inhibit the HIF-1 
signaling pathway
Menghang Xia*1, Kun Bi2, Ruili Huang1, Ming-Hsuang Cho1, 
Srilatha Sakamuru1, Susanne C Miller1, Hua Li3, Yi Sun3, John Printen2, 
Christopher P Austin1 and James Inglese1
Address: 1NIH Chemical Genomics Center, National Institutes of Health, Bethesda, MD 20892-3370, USA, 2Invitrogen - Discovery Sciences, 501 
Charmany Dr., Madison, WI 53719, USA and 3Department of Radiation Oncology, University of Michigan, Comprehensive Cancer Center, Ann 
Arbor, MI, USA
Email: Menghang Xia* - mxia@mail.nih.gov; Kun Bi - Kun.Bi@invitrogen.com; Ruili Huang - huangru@mail.nih.gov; Ming-
Hsuang Cho - chomi@mail.nih.gov; Srilatha Sakamuru - sakamurus@mail.nih.gov; Susanne C Miller - smille10@umd.edu; 
Hua Li - huali@med.umich.edu; Yi Sun - sunyi@med.umich.edu; John Printen - John.Printen@Invitrogen.com; 
Christopher P Austin - austinc@mail.nih.gov; James Inglese - jinglese@mail.nih.gov
* Corresponding author    
Abstract
Background: Hypoxia-inducible factor-1 (HIF-1) is the major hypoxia-regulated transcription
factor that regulates cellular responses to low oxygen environments. HIF-1 is composed of two
subunits: hypoxia-inducible HIF-1α and constitutively-expressed HIF-1β. During hypoxic
conditions, HIF-1α heterodimerizes with HIF-1β and translocates to the nucleus where the HIF-1
complex binds to the hypoxia-response element (HRE) and activates expression of target genes
implicated in cell growth and survival. HIF-1α protein expression is elevated in many solid tumors,
including those of the cervix and brain, where cells that are the greatest distance from blood
vessels, and therefore the most hypoxic, express the highest levels of HIF-1α. Therapeutic
blockade of the HIF-1 signaling pathway in cancer cells therefore provides an attractive strategy for
development of anticancer drugs. To identify small molecule inhibitors of the HIF-1 pathway, we
have developed a cell-based reporter gene assay and screened a large compound library by using a
quantitative high-throughput screening (qHTS) approach.
Results: The assay is based upon a β-lactamase reporter under the control of a HRE. We have
screened approximate 73,000 compounds by qHTS, with each compound tested over a range of
seven to fifteen concentrations. After qHTS we have rapidly identified three novel structural series
of HIF-1 pathway Inhibitors. Selected compounds in these series were also confirmed as inhibitors
in a HRE β-lactamase reporter gene assay induced by low oxygen and in a VEGF secretion assay.
Three of the four selected compounds tested showed significant inhibition of hypoxia-induced HIF-
1α accumulation by western blot analysis.
Conclusion: The use of β-lactamase reporter gene assays, in combination with qHTS, enabled the
rapid identification and prioritization of inhibitors specific to the hypoxia induced signaling pathway.
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Background
The maintenance of oxygen homeostasis is essential for
the human body. Hypoxia, defined as a reduction in the
normal level of tissue oxygen tension, is associated with
cancer, inflammation and ischemia [1]. The transcrip-
tional factor hypoxia-inducible factor 1 (HIF-1) is critical
in responding to hypoxic environments by inducing sur-
vival and anti-apoptotic genes. HIF-1 is composed of two
subunits: hypoxia-responsive HIF-1α and constitutively-
expressed HIF-1β (also known as ARNT, aryl hydrocarbon
receptor nuclear translocator) [2]. Under normal oxygen
tension, HIF-1α is rapidly degraded by the ubiquitin-pro-
teasome pathway [3,4], but under hypoxic conditions,
HIF-1α is stabilized by the attenuation of prolyl hydroxy-
lase activity [5,6]. The accumulated HIF-1α heterodimer-
izes with HIF-1β and translocates into the nucleus. The
HIF-1 complex binds to a hypoxia-response element
(HRE), composed of a core 5'-ACGTG-3' sequence, in
concert with the transcriptional coactivator p300/CBP [7],
thereby activating the expression of target genes, such as
vascular endothelial growth factor (VEGF) [8], erythropoi-
etin [9], and the glucose transporters GLUT1 and GLUT3
[10,11].
In many solid tumors, intratumor hypoxia up-regulates
HIF-1α expression, a response that is correlated with
increased angiogenesis, oncogenesis, and poor cancer
prognosis [12]. In HIF-1α knockout mice, loss of HIF-1α
in embryonic stem cells and endothelial cells dramatically
retards solid tumor and blood vessel growth, and a
reduced capacity to release angiogenic VEGF during
hypoxia [13,14]. Therefore, HIF-1 responsive tumor
hypoxia has become the focus of active biomedical inves-
tigations and its inhibition is emerging as a potentially
valuable and novel approach to cancer therapy. Several
small molecule inhibitors of HIF-1α activity are entering
clinical development [15-17], such as 2ME2 (2-methox-
yestradiol), an inhibitor of microtubule polymerization,
17-AAG (17-allylamino-17-demethoxygeldanamycin), a
HSP90 inhibitor, topotecan, a topoisomerase I inhibitor,
and PX-478 (S-2 amino -3- [4'-N,N,-bis (2-chloroethyl)
amino] phenyl propionic acid N-oxide dihydrochloride).
These compounds were reported to either inhibit intracel-
lular HIF-1α level or induce HIF-1α degradation [17]. Sev-
eral compounds have been in clinical trials, but none
appear very promising due to lack of target specificity and
low clinical efficacy [17].
In order to rapidly identify potent and specific inhibitors
of the HIF-1 pathway we developed a cell-based HIF-1
mediated  β-lactamase reporter gene assay and used a
quantitative high-throughput screening (qHTS) [18,19]
approach to test 73,000 compounds. The compounds
identified from the screen were further confirmed in sev-
eral follow-up studies including VEGF secretion assay.
This approach allowed us to rapidly and efficiently iden-
tify small molecule inhibitors of the HIF-1 signaling path-
way.
Results
Development and validation of a hypoxia responsive b-
lactamase reporter gene assay
We have generated a HRE-bla line in ME 180 cells, human
cervical cancer cells, by isolating a clonal cell line that
responds to hypoxic conditions by up-regulating β-lacta-
mase expression after fluorescence-activated cell sorting
(FACS) of cells in response to treatment with deferoxam-
ine (DFO), a known inducer of HIF-1 [20]. This line
expressed  β-lactamase in response to DFO and cobalt
chloride (CoCl2) (Figure 1A), both of which displace iron
from the prolyl hydroxylases F1H1 and PHD1-3, causing
its inhibition, to mimic the induction of hypoxic condi-
tions [21], with EC50s of 164 μM for DFO and 32 μM for
CoCl2, respectively. This response was also time depend-
ent with maximal β-lactamase expression after cells were
treated with DFO for 17 hrs (data not shown). The HRE β-
lactamase reporter gene assay (HRE-bla assay) was further
miniaturized into 1536-well plate format. In this format,
CoCl2 dose-dependently induced β-lactamase expression
with an EC50 of 54 μM, similar to that measured in 384-
well plate.
To date, three HIFα isoforms have been described, with
the best characterized being HIF-1α and HIF-2α. In can-
cer, the HIF system is up regulated both by microenviron-
mental hypoxia and by genetic events that lead to
enhanced translation or stability of HIF-1α[17]. While
HIF-1α has been shown to mediate hypoxia-induced
responses in ME-180 cells [22], we validated the HRE-bla
assay using HIF-1α and HIF-2α specific RNAi and exam-
ined the effect on HRE-bla  activity. Incubation of cells
with HIF-1α RNA duplexes blocked hypoxia-induced β-
lactamase expression, whereas HIF-2α duplexes had little
effect (Figure 1B and 1C). This result suggests that HIF-1α,
but not HIF-2α, regulates HIF-mediated gene expression
in ME-180 cells.
Identification of small molecule inhibitors of HIF-1 
pathway using qHTS
In the primary qHTS, 73,000 compounds were screened at
7-15 concentrations ranging from 0.5 nM to 38 μM in the
HRE-bla assay. The inhibitory effect of the compounds
was measured in the presence of 60 μM of CoCl2 in the
screen. NSC 607097, a known inhibitor of HIF-1 pathway
[23], was used as a positive control to examine the quality
of the results from each plate. The NSC 607097 concentra-
tion response curves reproduced well in all 500 plates
with an average IC50 of 0.29 ± 0.8 μM (Figure 2A). The
average signal to background ratio was 4.1 and Z' factor
averaged 0.7 for the entire screening. These data demon-Molecular Cancer 2009, 8:117 http://www.molecular-cancer.com/content/8/1/117
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A. HRE-bla ME-180 cells express β-lactamase in response to hypoxia Figure 1
A. HRE-bla ME-180 cells express β-lactamase in response to hypoxia. Cells were incubated with indicated amount of 
DFO or CoCl2 for 17 hrs before β-lactamase assay was performed. B. HIF1α, but not HIF2 α, mediates the expression 
of β-lactamase in response to hypoxia. Cells were incubated with indicated Stealth RNAi™ duplexes for 55 hrs, and then 
treated with 125 μM CoCl2 for 17 hrs before β-lactamase assay was performed. C. Western blot analysis for DFO-
induced HIFα accumulation and RNAi knockdown. Cells were incubated with indicated Stealth RNAi™ duplexes for 55 
hrs, and then treated with 250 μM DFO for 5 hrs before HIF1α western blot was performed as described in Materials and 
Methods.Molecular Cancer 2009, 8:117 http://www.molecular-cancer.com/content/8/1/117
Page 4 of 13
(page number not for citation purposes)
A. Intra-plate concentration response titration curves for NSC 607097 in the screening Figure 2
A. Intra-plate concentration response titration curves for NSC 607097 in the screening. Each curve was measured 
in duplicate in column 1 of each assay plate. B. qHTS concentration response data binned into curve classes 1-3 (Class 1 curves, 
blue; Class 2 curves, orange; Class 3 curves, green). C. Concentration response curves for compounds in series 39 (Class 1.1 
curves, blue; Class 1.2 curves, orange; Class 2.1 curves, green; Class 3 curves, light gray; Class 4 curves, dark gray).
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strate that the qHTS platform is robust and suitable for
identifying active compounds. Concentration-response
data for all the compounds screened binned into curve
classes are shown in Figure 2B.
In this primary qHTS (PubChem AID: 915), 350 inhibi-
tors (0.5% of library) with class 1.1, 1.2, and 2.1 curves in
the ratio readout (class 1-3 in the 460 nm reading and
class 4 in the 530 nm reading) were identified. The distri-
butions of curve class and potency for these compounds
were listed in Table 1. A structure-activity relationship
(SAR) analysis of these 350 compounds yielded 18 struc-
tural series each sharing a common scaffold (see Methods
section for details). Ten of these 18 series and 6 singletons
were selected for confirmation and follow up studies
based on compound potency/efficacy ranges, curve qual-
ity and cytotoxicity. The concentration response curves for
compounds in series 39 are showed in Figure 2C from the
primary screen. Details on the procedure used for series
prioritization can be found in the Materials and Methods
section.
Among these we further identified compounds from three
novel structural series (Figure 3A) that were the most
potent and had the highest quality concentration-
response curves for secondary testing in additional assays.
The thiophen-oxadiazole core, rather than the oxadiazole
group alone, seems to be important for compound activ-
ity in series 39 and 31. As shown in Figure 3B, of all the 64
compounds containing the thiophen-oxadiazole core, 7
(11%) were active and 54 were inactive; whereas of the
1329 compounds in the library containing only the oxa-
diazole moiety, only 21 (1.6%) were active.
NCGC00044926 was assigned to a different series (series
31 rather than 39), even though it contains the thiophen-
oxadiazole core as well. This is because NCGC00044926
also contains another scaffold, the methoxybenzothiazol-
amino group, which is the common scaffold for series 31.
Inhibition of CoCl2 and low oxygen induced HIF-1 
signaling
In the confirmation study 40 compounds (Table S1, Addi-
tional file 1) from 10 series and 6 singletons were pur-
chased and retested in the HRE-bla  assay induced by
CoCl2. Of the 40 compounds that had been tested in the
primary screen, 36 showed the same activity in the confir-
mation assay giving a confirmation rate of 90%. To con-
firm that the compounds were specifically active against
the HIF-1 mediated signaling pathway, we selected 10
from these 36 confirmed compounds based on potency
and structure novelty. These compounds were tested in
the same HRE-bla assay induced by low oxygen (≤1%) in
a hypoxia chamber. All the compounds inhibited low oxy-
gen-induced HIF-1 mediated signaling except for
NCGC00078922. Compounds from series 31 were the
most potent in both low oxygen and CoCl2-induced HRE-
bla  assays (Table 2). As shown in Figure 4A,
NCGC00043898 (series 39), NCGC00044926 (series 31),
NCGC00049606 (series 39) and NCGC00056044 (series
71) concentration-dependently inhibited HIF-1 mediated
signaling induced by low oxygen. These compounds
showed similar activities in a CoCl2-induced HRE-bla
assay (Figure 4B). To study the mechanism involved in the
inhibition of HIF-1 signaling, NCGC00043898,
NCGC00044926, NCGC00049606 and NCGC00056044
were further examined for their effect on HIF-1α accumu-
lation by western blot analysis. As shown in Figure S1
(Additional file 2), NCGC00043898 (series 39),
NCGC00049606 (series 39) and NCGC00056044 (series
71) significantly inhibited CoCl2 induced HIF-1α accu-
mulation at 10 μM and had even more inhibitory effect at
20 μM, whereas NCGC00044926 (series 31) showed little
inhibition, which indicates this compound does not
inhibit HIF-1α transcriptional activity via the inhibition
of HIF-1α accumulation.
In addition, the cytotoxicity of these compounds was
investigated in a cell viability assay which measures intra-
cellular ATP content. Only NCGC00056044 significantly
decreased intracellular ATP content with an IC50 of 15.8
μM after a 17 hr treatment. None of the other compounds
showed significant cytotoxicity. To further investigate the
effect of these four compounds on the growth of ME 180
cells under normoxic or hypoxic (induction by CoCl2)
conditions, intracellular ATP content was measured after
compound treatment for 24 to 72 hr. After a 24 hr treat-
ment, NCGC00056044 showed significant growth inhibi-
tion, while the others only showed minimal or no
inhibitory effect (Table S2, Additional file 3). After 48-72
hr treatment all the compounds had an inhibitory effect
on the growth of ME 180 cells. There was no significant
difference of compound IC50 values with or without
CoCl2 treatment.
Inhibition of hypoxia induced VEGF secretion
To determine whether these compounds were modulating
HIF-1 signaling, we evaluated the effect of theses com-
pounds on VEGF secretion in ME180 cells. Expression of
VEGF is induced in cells exposed to hypoxia [8], and VEGF
Table 1: Potency (half maximal inhibition concentration) 
distribution of active compounds in qHTS screening
Number of active compounds in curve classes
IC50 (μM) 1.1 1.2 2.1
< 0.10 4 12 0
0.10-1.0 16 33 7
1.0-10.0 60 40 86
10.0-100.0 2 2 88
Total 350Molecular Cancer 2009, 8:117 http://www.molecular-cancer.com/content/8/1/117
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Chemical structures of inhibitors for HIF-1 signaling pathway Figure 3
Chemical structures of inhibitors for HIF-1 signaling pathway. A. Four representative inhibitors from the qHTS. 
NCGC00044926 is a representative from series 31, NCGC00043898 and NCGC00049606 from series 39 and 
NCGC00056044 from series 71. B. Number of active and inactive compounds containing the 5-thiophen-1,2,4-oxadiazole core 
versus the 1,2,4-oxadiazole core. The thiophen-oxadiazole core appears to be important for compound activity. Right, Lead-
scope Maximal Common Substructures (MCS) used to populate series 31 and 39.
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is one of several well studied HIF-1 target genes [8,24].
Two known hypoxia inducers were used to induce VEGF
secretion in the assays, CoCl2 and iodochorohydrozyqui-
noline [25]. As shown in Figure 5, NCGC00043898
(series 39), NCGC00044926 (series 31), NCGC00049606
(series 39) and NCGC00056044 (series 71) concentra-
tion-dependently inhibited iodochorohydrozyquinoline
induced VEGF secretion, with IC50s of 23 μM, 15 μM, 25
μM and 10 μM, respectively. These compounds had a sim-
ilar inhibitory effect on CoCl2-induced VEGF secretion
(data not shown). However, a few compounds, including
NCGC00033933 and NCGC00078922, had no effect on
hypoxia induced VEGF secretion even though they
showed inhibitory effects in both low oxygen and CoCl2-
induced HRE-bla assays, suggesting that these compounds
may affect HIF-1 mediated target genes other than VEGF,
a result which warrants further investigation.
Selectivity of compounds in HRE signaling pathway
Some of the compounds screened against the HIF-1 path-
way were also tested in other signaling pathway assays at
the NCGC. We compared the activity, in terms of potency
and efficacy, of some of our confirmed active compounds
including NCGC00043898, NCGC00044926,
NCGC00049606 and NCGC00056044 in the HIF-1 path-
way with their activities in other pathways including AP-1
and NFκB signaling. Among these four compounds,
NCGC00044926 was inactive in both the AP-1-bla
(PubChem AID: 357) and NFκB-bla assays. In the AP-1
pathway screen using a β-lactamase assay,
NCGC00049606 and NCGC00056044 (PubChem AID:
357) showed partial efficacy with IC50s of 10 μM and 12.5
μM, respectively. The maximum inhibitory efficacies of
NCGC00049606 and NCGC00056044 in the AP-1 path-
way were 45% and 35%, respectively, whereas the inhibi-
tory efficacies of these two compounds in the HIF-1
pathway were 91% and 80%. In the NFκB reporter gene
assay, NCGC00056044 showed low potency (IC50, 10.5
μM) even though at full efficacy, while the other three
compounds were inactive. Finally, these compounds were
negative in an AmpC library profiling assay, indicating
that they were not inhibitors of the β-lactamase reporter
gene [26]. Taken together these results indicate that all
four compounds showed selective inhibitory activity
against the HIF-1 mediated signaling pathway, with mar-
ginal effect on the AP-1- and NFκB-mediated signaling
pathways.
Discussion
In the present study, we have engineered a ME180 cell line
with a β-lactamase reporter under the control of a HRE
that enables a reagent addition-only and microvolume (7
μL) screening assay for identifying small molecule inhibi-
tors of the canonical HIF-1 signaling pathway. We have
identified and confirmed compounds from several novel
structural series that are inhibitors of the HIF-1 mediated
pathway using a qHTS approach. These compounds
showed good potency/efficacy, specificity against this
pathway with no or low cytotoxicity, therefore might be
good candidates for further testing in other cancer cell
lines or animal models. The screening process and follow
up studies were summarized as a flow chart in Figure 6.
Assays designed for the identification of modulators of
the hypoxia pathway can be developed from individual
pathway proteins or cell-based systems. The former bio-
chemical assay allows identification of compounds
which, for example, directly bind to the HIF-1 protein
[27], but absent the cellular context which may influence
in vitro cell activity or regulation. Therefore pathway
assays can provide additional opportunities to modulate
the target activity, although can require considerable fol-
low-up studies to determine the specific site of action of
the compound. However, screening a compound collec-
tion against a cell-based HIF-1 assay, such as the β-lacta-
mase reporter gene assay, allows the identification of cell
membrane permeable HIF-1 inhibitors that can be rapidly
validated in secondary cell assays such as the hypoxia-
induced HIF-1α accumulation and VEGF secretion assays
used in this study.
The use of β-lactamase as a reporter with the cell-permea-
ble substrate, CCF4, permits the measurement of the
hypoxia response in live cells. The ratiometric readout by
using this β-lactamase substrate and dual emissions (460
and 530 nm) minimizes the well-to-well and plate-to-
plate variations caused by subtle differences in cell num-
bers that can result in the automated dispensing step. The
green fluorescence signal (530 nm) is reflective of the cel-
lular uptake of CCF4-AM substrate and can be used as an
indication of cell viability. Therefore, it can be used to
monitor compound cytotoxicity, independently from the
response due to β-lactamase inhibition reflective of the
pathway activity. For example, chetomin, a known HIF-1
inhibitor [28] with an IC50 value of 37.5 nM in this assay,
Table 2: Summary of compound activities (IC50, μM) in HRE-bla 
assay induced by ≤1% oxygen or CoCl2
Cluster Compound ID CoCl2 ≤1% Oxygen
Singleton NCGC00033933 0.013 0.84
Singleton NCGC00053249 5.62 14.8
71 NCGC00056044 3.16 1.56
23 NCGC00078922 6.31 Inactive
31 NCGC00044926 0.50 0.17
31 NCGC00043631 0.50 0.11
27 NCGC00043836 2.51 0.39
39 NCGC00043898 2.82 1.22
39 NCGC00044763 2.51 1.10
39 NCGC00049606 3.16 0.75Molecular Cancer 2009, 8:117 http://www.molecular-cancer.com/content/8/1/117
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was found to cause cytotoxicity at a concentration >200
nM under the induction of HIF-1 activity via CoCl2 [29].
The green fluorescence decreased as well as the blue fluo-
rescence (460 nm) for this compound, indicating that
chetomin inhibited CoCl2  induced HIF-1 activity and
resulted in cytotoxicity at high concentrations.
As the cell-based HIF-1 assay, conducted in the presence
of CoCl2, involves the activation of a β-lactamase reporter,
it may identify a number of non-specific inhibitors that
appear as positive either by competing with intracellular
iron or inhibiting mRNA transcription, protein synthesis
or β-lactamase activity. We have applied several follow-up
assays including functional assays that measure hypoxia-
induced HIF-1α accumulation and VEGF secretion, an
HRE-bla assay conducted in a hypoxia chamber (≤1% oxy-
gen), which serves as a confirmation assay of the CoCl2-
induced HRE-bla assay, and an assay that detects com-
pound cytotoxicity by measuring intracellular ATP con-
tent. In order to determine the specificity of the HIF-1
inhibitors identified from the primary screen and follow-
up study, we also examined their activity in other signal-
ing pathway assays run at the NCGC. The qHTS approach
combined with several follow-up studies allowed us to
efficiently identify the compounds capable of inhibiting
the HIF-1 signaling pathway. Of the ten structural series
and 6 singletons initially identified from qHTS,
NCGC00043898, NCGC00044926, NCGC00049606
and NCGC00056044 had their activity confirmed in all
follow-up studies, displaying potencies ranging from 0.5-
3 μM. These compounds have not been reported previ-
ously as inhibitors of the HIF-1 signaling pathway and
appeared to be selective toward this pathway as compared
to the NFκB and AP-1 signaling pathways. In addition, we
have demonstrated that these compounds blocked VEGF
secretion, a downstream response to activated HIF-1.
Using the qHTS approach potency and efficacy of each
compound can be obtained rapidly from the primary
screening data, limiting the amount of follow-up com-
pound acquisition and re-testing required. Confirmation
rates are greatly improved in qHTS compared to conven-
tional single concentration screening. For example, in our
follow-up studies 36 of 40 compounds re-tested positive,
a confirmation rate of 90%. We also confirmed thirteen of
the thirteen compounds in the NCI diversity collection
identified previously by two independent laboratories
[23,30] (Table S3, Additional file 4), although the meth-
ods of hypoxia induction were different among all three
labs. Of these compounds, NSC-259968 and NSC-
259969 showed a potent inhibitory effect on the HIF-1
signaling pathway with IC50s of 11.3 and 10.9 nM. Two
other compounds that were active are the DNA topoi-
somerase I inhibitors, NSC-606985 (camptothecin) and
NSC-609699 (topotecan) with IC50s of 69 nM and 240
nM, respectively. Chau et al [23] excluded NSC-606985
and NSC-609699 as potential inhibitors of HIF-1 signal-
ing due to their unacceptable cytotoxicity. We found that
all four compounds not only displayed cytotoxicity as
shown by a decrease in the green fluorescence signal (530
nm), but were also nonselective, as they blocked other
pathways such as the AP-1 and NF-κ-B pathways as well as
the HIF-1 signaling pathway (data not shown). The cyto-
toxicity of these compounds could not be detected in the
HRE-luciferase reporter gene assay where they were iden-
tified as active because both cytotoxicity and inhibition of
HIF-1 pathway would both result in a decrease in signal,
thus the two modes are indistinguishable in this assay for-
mat.
Conclusion
In summary, we have identified several novel small mole-
cule inhibitors of the HIF-1 signaling pathway by apply-
Effect of four novel inhibitors on HIF-1 signaling pathway Figure 4
Effect of four novel inhibitors on HIF-1 signaling 
pathway. Inhibition of HIF-1 mediated β-lactamase activity 
in HRE-bla ME-180 cells by various concentrations of 
NCGC00043898, NCGC00044926, NCGC00049606 and 
NCGC00056044 in the presence of 1% oxygen (A) and 60 
μM CoCl2 (B). The data are displayed as the percentage of 
control. Representative values are from a single experiment 
performed in duplicate. Data are expressed as mean ± SD.Molecular Cancer 2009, 8:117 http://www.molecular-cancer.com/content/8/1/117
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ing qHTS to a HRE-bla  assay and accessing the NIH
Molecular Libraries Small Molecule Repository. Activities
of selected compounds were confirmed in the follow-up
assays. Among these compounds, NCGC00043898,
NCGC00044926, NCGC00049606 and NCGC00056044
selectively inhibited both HIF-1 activity and VEGF protein
expression. Three of these compounds showed inhibition
of hypoxia-induced HIF-1α accumulation. Therefore, the
screening approach outlined here has allowed us to iden-
tify high quality lead compounds that can serve as probes
of the HIF-1 signaling pathway and as potential candi-
dates for future drug development.
Materials and methods
Cell lines and culture conditions
CellSensor® HRE-bla ME-180 cell line, generated in this
study, stably expresses a β-lactamase reporter gene under
the control of 5 copies of the HRE present in the VEGF
gene promoter. CellSensor® NFκB -bla and AP-1-bla ME-
180 cell lines were obtained from Invitrogen (Invitrogen,
Carlsbad, CA). CellSensor® NFκB-bla  ME-180 cells and
CellSensor® AP-1 (activator protein 1)-bla  ME-180 cells
contain a β-lactamase reporter gene under the control of
the NFκB response element or the AP-1 binding element,
respectively. Cells were cultured in DMEM medium sup-
plemented with 10% dialyzed fetal bovine serum, 2 mM
L-glutamine, 0.1 mM non-essential amino acids, 1 mM
sodium pyruvate, 25 mM HEPES, 50 U/ml penicillin and
50  μg/ml streptomycin, and 5 μg/ml of blasticidin at
37°C under a humidified atmosphere and 5% CO2.
HIF-1 RNAi assay and Western blot analysis
Cells were plated into a 96-well assay plate at 8000 cells/
100 μL/well in growth medium and after overnight incu-
bation at 37°C, 80 nM Stealth RNAi™ (Invitrogen)
duplexes in Lipofactamine™ 2000 (Invitrogen) in OPTI-
MEM was added. Cells were incubated for 48 hrs, the
medium was replaced with OPTI-MEM plus 0.5% dia-
lyzed FBS, and the indicated amount of CoCl2 or deferox-
amine (DFO) added. After 17 hrs incubation at 37°C, β-
lactamase activity was measured.
For Western blot analysis, cells were plated in 6-well plate,
mock transfected or transfected with indicated Stealth
RNAi™ oligos as described above for 55 hrs, and then were
left untreated or treated with 200 uM CoCl2 for 5 hrs. Cells
were harvested and incubated with M-PER cell lysis buffer
(Thermo Scientific) supplemented with protease inhibitor
cocktail (Sigma, St. Louis, MO) and DNAase I (Invitro-
gen) for 15 min on ice. Samples for SDS-PAGE were pre-
pared by addition of 5× SDS loading buffer and DTT (1
mM) to the cell lysates. Samples were boiled at 90°C for
3 min and then loaded onto a 4-20% Tris-Glycine gel.
Resolved proteins were transferred to nitrocellulose mem-
brane using the iBlot semi-dry transfer unit (Invitrogen).
The western blotting was then performed using primary
anti-HIF-1α antibody (Cell Signaling Technologies, Dan-
vers, MA) and alkaline-phosphatase conjugated secondary
goat anti-rabbit antibody (Invitrogen). Reactive bands
were detected using a chromogenic substrate reagent
(BCIP/NBT) (Invitrogen).
HRE  -lactamase reporter assay
HRE-bla  ME-180 cells were dissociated with 0.05%
trypsin/EDTA, washed in assay medium (OPTI-MEM with
0.5% fetal bovine serum, 0.1 mM nonessential amino
acids, 1 mM sodium pyruvate, 10 mM HEPES pH 7.3, 100
U/ml penicillin, and 100 μg/ml streptomycin), and sus-
pended in assay medium. As described in Table 3, cells
were dispensed at 2500 cells/5 μL/well in 1536-well black
wall/clear bottom plates (Greiner Bio-One North Amer-
ica, Monroe, NC) using a Flying Reagent Dispenser [31]
(FRD, Aurora Discovery, Carlsbad, CA). Twenty-three nL
of compound was transferred to the assay plate by a pin
tool [32] (Kalypsys, San Diego, CA) resulting in a 261-fold
dilution. One μL of medium with or without agonist or
agonist plus inhibitor was dispensed by a FRD in the fol-
lowing format. Column 1, NSC 607097 [23], a known
inhibitor of HIF-1 pathway, concentration-response titra-
tion from 0.6 nM to 2 μM, column 2, 120 μM CoCl2
(EC100), column 3, DMSO only, and columns 1, 4 to 48,
60  μM CoCl2. The plates were incubated 17 hours at
37°C. One μL of LiveBLAzer™ B/G FRET substrate (Invit-
rogen) detection mixture was added, the plates were incu-
bated at room temperature for 2.5 hrs, and fluorescence
intensity (405 nm excitation, and 460 and 530 nm emis-
Inhibition of hypoxia-induced VEGF secretion Figure 5
Inhibition of hypoxia-induced VEGF secretion. ME-180 
cells were pre-treated with NCGC00043898, 
NCGC00044926, NCGC00049606 and NCGC00056044 at 
various concentrations for 5 min and then exposed to 15 μM 
iodochorohydrozyquinoline for 17 hrs. Then VEGF level was 
determined by human VEGF ELISA kit. Representative values 
are from a single experiment performed in duplicate. Data 
are expressed as mean ± SD.Molecular Cancer 2009, 8:117 http://www.molecular-cancer.com/content/8/1/117
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sions) was measured by an Envision plate reader (Perkin
Elmer, Shelton, CT). Data was expressed as the ratio of
460/530 nm emissions.
In the confirmation study, the selected compounds were
first tested in HRE-bla assay induced by 60 μM CoCl2. The
assay protocol is same as above described except the dose
titrations were within one 1536-well plate and com-
pounds were tested at 24 concentrations in duplicate. In
the compound follow up, the activity of compounds was
further confirmed in HRE-bla assay in the presence of ≤1%
oxygen in a hypoxia chamber (Billups-Rothenberg, Inc,
CA). The process of compound selection will be described
in the following section.
qHTS and SAR analysis
Approximately 73,000 compounds were screened in this
qHTS [18,19,33]. Eighty-two percent of these compounds
A flowchart of identification of HIF-1 inhibitors Figure 6
A flowchart of identification of HIF-1 inhibitors. * 350 inhibitory compounds were identified from primary screening, in 
which 18 structure series were generated by using Leadscope fingerprints. ** A set of criteria (Table S4, Additional file 5) were 
applied to exclude series containing potentially fluorescent compounds and series with low potencies or efficacies, resulting in 
10 prioritized series and 6 singletons (Table S1, Additional file 1).
Table 3: qHTS protocol
Step Parameter Value Description
1 Plate cells 5 μL 2500 HRE-bla Cells
2 Incubation time 4-6 hr Cells adhere and acclimate
3 Library Compound
Control Compound
23 nL
23 nL
38 μM to 0.5 nM titration series
0.1 nM to 2 μM titrations
(NSC 607097)
4 Reagent 1 μL Buffer +/- agonist
5 Incubation time 17 hrs Induce HRE reporter gene
6 Reagent 1 μL β-Lactamase detection mixture
7 Incubation 2.5 hrs Cells load and cleave dye
8 Assay Readout Ex = 405/8 nm Envision
Notes
1 Black clear bottom 1536-well plates, single tip dispense of 2500 cells/well into all wells
2 37°C, 5% CO2 incubator
3 Pintool transfer of library to columns 5-48, and controls to columns 1-4.
4 Single tip dispense for each reagent, Column 1 and 4-48, agonist-60 μM CoCl2. Column 2, agonist-120 μM CoCl2. Column 3, buffer only.
5 37°C, 5% CO2 incubator
6 Single tip dispense of 0.6 μM CCF4-AM, 1 mg/ml Pluronic F127 surfactant, 3.5% PEG 400, 2.6% TR40, 2 mM probenecid, 0.1% DMSO
8 460/25 nm and 530/20 nm emission filtersMolecular Cancer 2009, 8:117 http://www.molecular-cancer.com/content/8/1/117
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come from the Molecular Libraries Screening Centers Net-
work (MLSCN) library collection, 15% from targeted
libraries, 1% from natural products and 2% from known
bioactives. Compound plates were prepared as inter-plate
titrations of at least seven dilutions with the four left-most
columns left empty in each plate [34]. Pin tool transfer of
compounds to assay plates resulted in a 261-fold dilution.
The final compound concentration in the 6 μl assay vol-
ume ranged from 0.0024 to 38 μM. Primary data analysis
was performed as previously described [18]. Briefly, raw
plate reads for each titration point were first normalized
relative to CoCl2 control (60 μM, 100%) and DMSO only
wells (basal, 0%), and then corrected by applying a pat-
tern correction algorithm using compound-free control
plates (DMSO plates) between each library of the com-
pound plate stack. Concentration-response titration
points for each compound were fitted to the Hill equation
yielding concentrations of half-maximal activity (IC50)
and maximal response (efficacy) values. Compounds
from qHTS were designated as Class 1-4 according to the
type of concentration-response curve observed [18].
Curve classes are heuristic measures of data confidence,
classifying concentration responses on the basis of effi-
cacy, number of data points showing above background
activity, and the quality of fit. Briefly, compounds that did
not show any concentration response or had no signifi-
cant activity point were classified as Class 4; compounds
only displayed significant activity at the highest tested
concentration were classified as Class 3; and compounds
with other types of concentration-response curves were
classified as either Class 1 - compounds with complete
response curves, or Class 2 - compounds with incomplete
response curves. Compounds with Class 1 or 2 curves
were further divided into subclasses based on efficacy and
quality of fit (r2). Compounds with good quality curves
and high efficacies (>80%) were designated as subclass
1.1 or 2.1, and low but significant efficacies (30-80%) as
subclass 1.2 or 2.2. Compounds with Class 1.1, 1.2 or 2.1
curves were generally selected for follow up analyses as
they represented high confidence data. Compounds with
Class 4 curves in the 530 nm reading, Class 1-3 in the 460
nm reading, and Class 1.1, 1.2 or 2.1 in the ratio determi-
nation were defined as active inhibitors and selected for
structure-activity relationships (SAR) analysis. To identify
active scaffolds, selected compounds were clustered using
Leadscope®  fingerprints, yielding 72 clusters. Maximal
common substructures (MCS) were extracted from each
cluster containing at least 4 active compounds, which
were then used to search the entire screening collection to
find all analogs, including inactives, yielding 18 series
(compounds sharing a common scaffold formed a series).
A set of criteria (Table S4, Additional file 5) were applied
to exclude series containing potentially fluorescent com-
pounds and series with low potencies or efficacies, result-
ing in 10 prioritized series and 6 singletons.
Measurement of VEGF secretion
HRE-bla cells were plated in growth medium at 1 × 105
cells/well in a 24-well plate. After incubation for 3-5 hrs at
37°C, the cell culture medium was removed and OPTI-
MEM medium with 1% dialyzed FBS was added into the
wells. The cells were then treated with compound for 5
min, followed by addition of 15 μM of iodochorohydro-
zyquinoline or 60 μM CoCl2. After 20 hr treatment, the
culture media were removed and analyzed for VEGF
expression using human VEGF immunoassay kit (R&D
Systems, Minneapolis, MN). Briefly, 200 uL of sample or
known standard (0-2000 pg/ml) was added to wells of a
microplate which was pre-coated with a monoclonal anti-
body specific VEGF and incubated at room temperature
for 2 hrs. After washing away any unbound substances, an
anti-VEGF antibody conjugated to horseradish peroxidase
was added and the plate incubated for 2 hrs at room tem-
perature. Following three washes, a substrate solution was
added and incubated for 20 min, followed by the addition
of a stop solution. The optical density of each well was
determined using an EnVision plate reader at 450 nm
with 570 nm as a reference filter.
NFkB and AP-1 b-lactamase reporter assays
NFκB-bla or AP-1-bla ME-180 cells were dissociated with
0.05% trypsin/EDTA, resuspended in assay medium, and
dispensed at 2000-2500 cells/5 μL/well in 1536-well
black wall/clear bottom plates (Greiner Bio-One North
America) using a FRD. Twenty-three nL of compound was
transferred to the assay plate by a pin tool (Kalypsys)
resulting in a 261-fold dilution. For NFκB assay, 1 μL of
medium with or without 1 ng/ml TNF-α was dispensed by
a FRD, and for AP-1 assay 1 μL of medium with or without
1 ng/ml EGF was dispensed by a FRD. After the plates were
incubated 5 hrs at 37°C, one μL of LiveBLAzer™ B/G FRET
substrate (Invitrogen, CA) detection mixture was added.
The plates incubated at room temperature for 2 hrs, and
fluorescence intensity (405 nm excitation, 460 nm and
530 nm emissions) was measured by an Envision plate
reader. Data was expressed as the ratio of 460/530 nm
emissions.
Cell viability assay
Cell viability was measured using a luciferase-coupled
ATP quantitation assay (CellTiter-Glo®, Promega, Madi-
son, WI). Cells were dispensed at 2500 cells/well in 1536-
well white/solid bottom assay plates (Greiner Bio-One
North America) using a FRD. The cells were incubated at
37°C for 4-6 hrs to allow for cell attachment, followed by
addition of compounds via pin tool. After compound
addition, plates were incubated for 17-72 hrs at 37°C. At
the end of the incubation period, 5 μL of CellTiter-Glo®
reagent was added, plates were incubated at room temper-
ature for 30 min, and luminescence intensity determined
using a ViewLux plate reader (PerkinElmer, Shelton, CT).Molecular Cancer 2009, 8:117 http://www.molecular-cancer.com/content/8/1/117
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